This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Newsletter Archive
Prostate Cancer Weekly
UroAlerts - Prostate Cancer Weekly
July 09, 2024
Videos
Peer-to-Peer Clinical Conversations
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
Karim Fizazi
Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial.
View
Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand? - Kae Jack Tay
Kae Jack Tay
Zach Klaassen interviews Jack Tay about the evolution and current practices in focal therapy for prostate cancer.
View
Beyond the Abstracts
The Association of County-Level Prostate-Specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality - Beyond the Abstract
Positive Surgical Margins after Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration - Beyond the Abstract
Conference Coverage
ASCO GU 2024: Homologous Recombination Repair Gene Mutation Testing Patterns and Treatment Selection from a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO 2024: Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer
ASCO 2024: Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial
AUA 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib (AZD5305) in Combination with New Hormonal Agents in Patients with mCSPC +/- HRR Mutations
EAU 2024: Early Oncological Outcomes Following Radical Prostatectomy of Patients with Pelvic Lymph Node-Positive Prostate Cancer at Preoperative PSMA PET/CT
Articles
Editor Selected Abstracts and Commentaries
Prostate Cancer
Fluorine-18 Prostate-Specific Membrane Antigen–1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer
Circulating Tumor Extracellular Vesicles to Monitor Metastatic Prostate Cancer Genomics and Transcriptomic Evolution
Early Prostate Cancer Deaths Among Men With Higher vs Lower Genetic Risk.
Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer.
Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study.
Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry.
Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial.
A case-cohort study of per- and polyfluoroalkyl substance concentrations and incident prostate cancer in the Cancer Prevention Study-II LifeLink Cohort study.
Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions.
Coffee, PI3K signaling pathway, and prostate cancer: a prospective study in the Health Professionals Follow-up Study.
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening.
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Predicting Peak Productivity in Urologic Medicare Practice via Work-Relative Value Units
Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm.
shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer.
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.
Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models.
MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT.
Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment.
Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen.
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy.
A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy.
Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity.
Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men.
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms.
Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.
Focal Therapy in Grade Group 3 Prostate Cancer.
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer.
Comparative analysis of genetic risk scores for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy.
The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy.
Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost.
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer?
Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study.
A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer.
Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer.
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
Social integration and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study.
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
Variation in Management of Lymph Node Positive Prostate Cancer After Radical Prostatectomy Within a Statewide Quality Improvement Consortium - Beyond the Abstract
Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set - Beyond the Abstract
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2024 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free